Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration
Hae Won Lee, Hyungjin Kim, Ji Seo Park, Jae Hwa Lee, Jin Ju Park, Mi-Ri Gwon, Joo-Youn Cho, Sook Jin Seong, Young-Ran Yoon · 2026
Read Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration by Hae Won Lee, Hyungjin Kim, Ji Seo Park, Jae Hwa Lee, Jin Ju Park, Mi-Ri Gwon, Joo-Youn Cho, Sook Jin Seong, Young-Ran Yoon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13222617.txt.
Description
Hae Won Lee and co-authors compare how the diabetes drug dapagliflozin behaves in obese versus nonobese healthy adults, in a 2026 pharmacology study. Twenty-two volunteers took ten milligrams daily for five days. Blood sampling after the last dose mapped drug exposure, and statistical analyses probed whether body weight explains any gap.
Obese participants showed lower overall exposure and lower peak levels than nonobese participants at steady state. No strong direct correlation appeared between single weight measures and the drug parameters, though adjusted analyses were run to test weight as an explanation. Since the drug also trims body weight, knowing that obesity itself shifts its handling helps interpret dosing across patient sizes.
Catalog record
| CREATOR | Hae Won Lee, Hyungjin Kim, Ji Seo Park, Jae Hwa Lee, Jin Ju Park, Mi-Ri Gwon, Joo-Youn Cho, Sook Jin Seong, Young-Ran Yoon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |